- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- S-4/A Registration of securities issued in business combination transactions
- 5.1 EX-5.1
- 10.15 EX-10.15
- 10.16 EX-10.16
- 10.17 EX-10.17
- 10.18 EX-10.18
- 10.19 EX-10.19
- 10.20 EX-10.20
- 10.21 EX-10.21
- 10.22 EX-10.22
- 10.23 EX-10.23
- 10.24 EX-10.24
- 10.25 EX-10.25
- 10.26 EX-10.26
- 10.27 EX-10.27
- 10.28 EX-10.28
- 10.29 EX-10.29
- 10.30 EX-10.30
- 10.31 EX-10.31
- 10.32 EX-10.32
- 10.33 EX-10.33
- 10.34 EX-10.34
- 10.35 EX-10.35
- 10.36 EX-10.36
- 10.37 EX-10.37
- 10.38 EX-10.38
- 10.39 EX-10.39
- 10.40 EX-10.40
- 10.41 EX-10.41
- 10.42 EX-10.42
- 10.43 EX-10.43
- 10.44 EX-10.44
- 10.45 EX-10.45
- 10.46 EX-10.46
- 10.47 EX-10.47
- 10.48 EX-10.48
- 10.49 EX-10.49
- 10.50 EX-10.50
- 10.51 EX-10.51
- 10.52 EX-10.52
- 10.53 EX-10.53
- 23.1 EX-23.1
- 23.2 EX-23.2
- 99.1 EX-99.1
- 99.2 EX-99.2
- 99.7 EX-99.7
- Download Excel data file
- View Excel data file
- 13 Jul 23 424B3 Prospectus supplement
- 3 Jul 23 424B3 Prospectus supplement
- 7 Jun 23 EFFECT Notice of effectiveness
- 6 Jun 23 424B3 Prospectus supplement
-
2 Jun 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 27 Apr 23 S-4 Registration of securities issued in business combination transactions
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” in the Amendment #1 to the joint proxy statement/prospectus, which is part of the Registration Statement (Form S-4) of MEI Pharma, Inc., and to the inclusion in such Registration Statement of our report (which contains an explanatory paragraph describing conditions that raise substantial doubt about Infinity Pharmaceuticals, Inc.’s ability to continue as a going concern as described in Note 2 to Infinity Pharmaceuticals, Inc.’s consolidated financial statements) dated March 28, 2023 with respect to the consolidated financial statements of Infinity Pharmaceuticals, Inc., included in Infinity Pharmaceuticals, Inc.’s Annual Report (Form 10-K) for the year ended December 31, 2022, filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP |
Boston, Massachusetts |
June 2, 2023 |